Jump Financial’s Viridian Therapeutics VRDN Stock Holding History

Jump Financial’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.32M	Buy	398,251 +334,140	+521%	+$5.38M	0.06%	362
2026 Q1	$1.25M	Buy	+64,111	New	+$1.9M	0.02%	836
2024 Q4	–	Sell	-141,978	Closed	-$3.23M	–	2051
2024 Q3	$3.23M	Buy	141,978 +123,178	+655%	+$2.01M	0.07%	345
2024 Q2	$245K	Buy	+18,800	New	+$260K	﹤0.01%	1469
2023 Q4	–	Sell	-61,654	Closed	-$946K	–	2294
2023 Q3	$946K	Buy	61,654 +12,623	+26%	+$241K	0.04%	696
2023 Q2	$1.17M	Sell	49,031 -2,716	-5%	-$69.7K	0.04%	603
2023 Q1	$1.32M	Buy	51,747 +21,962	+74%	+$704K	0.05%	502
2022 Q4	$870K	Sell	29,785 -7,230	-20%	-$167K	0.05%	539
2022 Q3	$760K	Buy	37,015 +10,387	+39%	+$187K	0.03%	727
2022 Q2	$308K	Buy	+26,628	New	+$358K	0.01%	1055

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jump Financial's VRDN Position: Q2 2026 in Review

Jump Financial increased its Viridian Therapeutics (VRDN) stake by 521% in Q2 2026, buying an estimated $5.38M and bringing the position to 398,251 shares worth $7.32M. The position accounts for 0.06% of the portfolio, ranked #362.

Jump Financial first reported a position in VRDN in Q2 2022 and has held it in 10 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Jump Financial held 398,251 shares of Viridian Therapeutics worth $7.32M as of Q2 2026.
Jump Financial bought 334,140 Viridian Therapeutics shares in Q2 2026, an estimated $5.38M.
Viridian Therapeutics made up 0.06% of Jump Financial's portfolio in Q2 2026, its #362 holding.
Jump Financial first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 10 quarters since.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.